Thermo Fisher Scientific (TMO) Stock Looks Near Fair Value Following A 24% Run
Thermo Fisher Scientific stock has delivered a strong 23.6% gain over the past year, yet current checks suggest the shares now trade close to an intrinsic value estimate rather than at a clear discount. With market multiples also looking roughly in line, the question for you is whether recent gains already reflect much of the company’s long term cash flow potential.
- The share price return of 23.6% over the past year points to solid recent performance that could limit how much more upside is available without a change in expectations.
- Growing interest in areas such as protein design and engineering can support long term demand for Thermo Fisher Scientific’s tools and services, while any setback in these markets or in broader life sciences spending may weigh on future cash flow expectations.
- The broader valuation checks show a mixed picture rather than a clear bargain or clear overvaluation, with a value score of 4.0 and an intrinsic value estimate from a Discounted Cash Flow (DCF) model that sits close to the current market price.
The issue now is whether Thermo Fisher Scientific’s current price fairly reflects its long term cash flow outlook or if the recent climb has left the stock pricing in too much optimism.
Compare Thermo Fisher Scientific’s recent 23.6% one year return and mixed valuation checks with other potential opportunities by scanning 50 high quality undervalued stocks, which currently look priced below their estimated quality.
Where Does Thermo Fisher Scientific Sit on Cash Flow?
The Discounted Cash Flow model values Thermo Fisher Scientific by projecting the cash it can return to shareholders over time and discounting that back to today. On this approach, the company is modeled with growing free cash flows, starting from about $7.4b in the latest twelve months and rising over the coming decade.
Those projections feed into an estimated intrinsic value of about $635 per share, which sits only slightly above the current market price and implies the stock is roughly fairly valued. Despite the recent focus on AI driven protein design and engineering, which keeps attention on life science tools providers, the DCF output suggests the current share price already captures much of Thermo Fisher Scientific’s expected cash generation.
Overall, Thermo Fisher Scientific stock appears to be trading close to fair value based on its projected cash flows and current price.
Thermo Fisher Scientific is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Where Does Thermo Fisher Scientific Sit on Earnings?
P/E is a useful check for Thermo Fisher Scientific because earnings remain a core measure of how the market is pricing its established life sciences franchise. The stock trades on a P/E of about 31.9x, which is slightly below the Life Sciences industry average of roughly 37.3x and also below the peer group average of about 33.7x.
A tailored fair P/E ratio for Thermo Fisher Scientific, which blends factors such as its scale, margins and risk profile, sits at around 32.1x. That is very close to the current 31.9x multiple, so the shares do not screen as obviously cheap or expensive based on earnings alone. The market’s pricing here is broadly in line with what this framework suggests you might expect for the stock today.
On the P/E multiple, Thermo Fisher Scientific currently looks priced at roughly fair value.
See what the numbers say about this price — find out in our valuation breakdown.
The Thermo Fisher Scientific Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Thermo Fisher Scientific’s valuation checks leave off. They make clear which growth, margin and earnings paths would need to play out for the stock to be worth materially more or less than today’s price. Each Narrative links a fair value estimate to a defined storyline about Thermo Fisher Scientific's potential catalysts and risks. You can use that to track which version of events appears to be unfolding on the Community page.
The community views on Thermo Fisher Scientific are pulled in opposite directions, with one side focused on long term tools demand and the other on structural growth risks.
Bull case: roughly fairly valued
"Strong momentum in high-impact innovation evidenced by next-generation analytical tools like the Orbitrap mass spectrometers and AI integration into drug development workflows positions Thermo Fisher to capture incremental share as genomics and precision medicine proliferate…"
Read the full Bull Case to see why Thermo Fisher Scientific could be undervalued
Bear case: 12% overvalued
"Accelerating geopolitical tensions and trade restrictions, especially between the U.S. and China, are expected to significantly disrupt Thermo Fisher's global supply chains, create persistent cost headwinds, and limit growth opportunities in key international markets, thereby putting long-term pressure on both revenue and net margins…"
Read the full Bear Case to see why Thermo Fisher Scientific could be overvalued
Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!
The Bottom Line
Thermo Fisher Scientific now looks roughly fairly valued on both the Discounted Cash Flow (DCF) view and the P/E multiple, so the easy valuation argument is largely gone for new money. The mixed value score underlines that there is no clear discount, but also no glaring overvaluation based on the checks used here. From this point, the key question is whether Thermo Fisher Scientific can sustain cash flow and earnings strong enough to justify holding a market level multiple through cycles in life sciences spending and any disruption from geopolitical or regulatory pressure.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com